€25.50
Your prediction
Financial data and news for Intellia
sharewise wants to provide you with the best news and tools for Intellia, so we directly link to the best financial data sources.
Financials
News
Better Cathie Wood Stock: Moderna vs. Intellia
Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because
Is Intellia Therapeutics Stock a Buy Now?
Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
The day after Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
You've no doubt seen mutual fund warnings that past performance isn't necessarily indicative of future results. This caution applies to stocks as well. However, it doesn't just mean that investments
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
Cathie Wood's success is based on two main things: finding innovators and betting on them for the long term. The founder and chief executive officer of Ark Invest goes for innovators in all areas
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood trounced the market in 2020, with her aggressive investing style helping Ark Invest's family of exchange-traded funds outperform. She beat the market again in 2023 after back-to-back
Is It Too Late to Buy Intellia Therapeutics Stock?
Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NASDAQ: NTLA) afloat. The
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
You've probably heard that bleeding-edge biotechs like Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) are working hard to develop gene therapies to cure intractable
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (NASDAQ:
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
When it comes to picking winning biotech companies, sometimes it pays to go with players who are at the cutting edge of their field. On Oct. 18, regulators at the Food and Drug Administration (FDA)
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too
Cathie Woods, through her various ARK funds, has been scooping up shares of Intellia Therapeutics (NASDAQ: NTLA), Block (NYSE: SQ), and Ginkgo Bioworks (NYSE: DNA) lately. All three stocks have
2 Brilliant Growth Stocks to Buy and Hold Forever
Over the course of 2007 to 2021, growth stocks dramatically outperformed value stocks. Historically low interest rates, coupled with the emergence of the knowledge economy, sparked one of the
Down 45%, Is Intellia a Buy?
Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron
This Cathie Wood Stock Is Poised to Double, Says Wall Street
Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a